Tubulin inhibitors. Selected scaffolds and main trends in the design of novel anticancer and antiparasitic agents
Authors:
Open Access
- 30 December 2023
- journal article
- research article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 143, 107076
Abstract
No abstract availableKeywords
This publication has 155 references indexed in Scilit:
- Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trialBritish Journal of Cancer, 2012
- Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxelInvestigational New Drugs, 2011
- Microtubules as antifungal and antiparasitic drug targetsExpert Opinion on Therapeutic Patents, 2011
- Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancerDrugs of Today, 2010
- ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculatureAnti-Cancer Drugs, 2009
- A History of Cancer ChemotherapyCancer Research, 2008
- Microtubules as antiparasitic drug targetsExpert Opinion on Drug Discovery, 2008
- Discovery and development of antimitotic agents that inhibit tubulin polymerisation for the treatment of cancerExpert Opinion on Therapeutic Patents, 2002
- Binding of maytansine to rat brain tubulinBiochemical and Biophysical Research Communications, 1976
- The binding of vincristine, vinblastine and colchicine to tubulinBiochemical and Biophysical Research Communications, 1972